2021-12-31-accounts

This text was generated using OCR and may contain errors. Check the original PDF to see the document submitted to the regulator.

UROFOUNDATIONLoGy('\

THE UROLOGY FOUNDATION

TRUSTEES’ ANNUAL REPORT & FINANCIAL STATEMENTS DECEMBER 2021

----- Start of picture text -----
Rita 4
UNDA M6
----- End of picture text -----

Chairman’ sistatemMentvssissccssssecisiscsossseswemeases sssermasarsrswemecsneseriseaserevawTaeeeEeTee
Overview Of the year ......... ccc ese ecece eee eenceeeeteeeeeeeeeseeeeeseeeeseeeseseetsseeeessetsnssetsseeeseeeeD
Objectivesianid ACtivitieS wxccrssecsseersesecss vers ecnesmereranen enna ee ree 4
Our Visionsand MISSION césescewssaceewsannananwansmeacamamanneaecsaunamanr enna ene eNeeaTenaoammenel’
QUE ValGS raizs sesscrcress artic arse, tits, ate share sbi, tna ais NG shina adic Sls Nias SENG NUL SEG SEN.aIS NN clea TS cm waa
What We dO sivessrswsssssewexewess sewessarserenaarrears aeerne sea aeerumV eR Rese TEA
PUDLIC Benefit sescsccsesveamssnmeannamscamansnmcnunraner naan ans veaewRUeERATTEMaNETTRTMESTTREENRTET OD)
Grants POLICY ......... cece ecece ececeeee cecenetseeeeeeeeeeeseeeeeseeeeeeeteeseeeeessseeeeeeeessseeeetstsseseeeeesD
Comparison Of2020 V 2021 .......... ccc ceececececeeeeeeeeeeeeseeneeeeeeneeeeeeetseessesscesssesssessserseesseesesO
Achievements and Performance in 2021 wwcicccesssscescvssesscessoevevesveeseevecssversuseseevereceeersesseeas7
1. Seeking better treatments and cures through research .............cceeeeese eeeeeeceeecetecesceeeee D
2. Improving knowledge and skills through training ............... cccece eeeeeeeeeeeeeseetceetceseeeneeen D
3. Improve public awareness of urological conditions and symptoms .................0eeeeeeeeeeee 10
A Plansfor thecfuturssswscsssnsansiemeenannnamessaamnwmnnneonn renameseaseimemmeenmcannecen TE
Financial REViOW ........... cece sce eec cece enceeeeeeeceneeeteeeteeeneeeeeeseeeseeteestsesseesseessestsestsesscesee TZ
Financial. Results of Activities & EVeNtS 2cse2cesswerewrcceseweer neve seessen veeweessoxeeerneseecese 12
FUNCIAISING ss:ccesnesensceeesssmceeimesnersseware rere emnecpmNGRenT reeEMNTT EEE NTO TZ
Reserves& Liquidity Policy ............ cc cece ccccceceee eence ceceeeececeeeesseeeseesseseeeesesssseeeeessseees TZ
Statement Of GOING CONCEMN .........eecee ese e eee e eeeeeeteeeeeeeeesseeeesssesescessscessssecessseseseseses TD
Investments: POLICYssecserssssw2sensesssnewenemeamr arcuateeeeueeeeeer e e 13
Remuneration policy wsscesssccreevsnesesweesrsswenscossenseaweesouemer vi e reve viweseeversm ceressecrecas) 13
PeNSIONS POLICY......... ccccececes esseeceseeeeeseeeeeseeeeeeeeeessesscesssecessssetssesesstseessssessssessseees IS
Equal opportunities and diversityPOlicy.............. ceceesceeeeeeeeeceeesceestcetsssessssseesseessssees I
Principal. risks atid UNCEFtaINtiGS sscesscsscsscecscavecssvecsrmasemneemnemeeeens’ 14
Structure; Governance:& Management .<cssiscessssagasecsewensseceusespesseeresse esew e sewsger e yo vegess:16
Charity Governance Code...........cececeeescceesceeeeeceessecesesccssseeessseessseeessssesssesessseesseseses 10
Trustee Recruitment, Training and INCUCtION .............ceseeece seceeeceeeceseeescetscessetseetseessees 10
Appointment’&ElectlONiescccsvisewscemsep sesseaseennenemer weroases 16
Relationships with Related Parties: s.cissescssssscasessesnwssavesnsuprereevesrwaressvwerererveevesseeseeeees: 17
Representation on Other Bodies ..............ccecececeeessceceeeesseceeeesssecceecesssscesessssscceeessssees TL
Reference and administrative details............ cceceeeseeeeeseeeeceeeeeteeeseeesssesssssssesesesessseseseees 10
THUStOCCS vxccsscccosiweusarmaasaw sens spaneemeassnesslemeak ees eemeaueers EeRE EESSEEE UreESEERTENET 16
REGIStered ONC Cherie cassmnsees nearnessammeraareammnneennie nnn eRnNe i iRAM CERNE IO
AUCILOIS 20.0... ccece cecececenee eee te eeeneeeeneeeeneeeneeeeeseeeeeseessteeesesetessseessssesssseetssseessceees 18
Trustees’ & Directors’ Responsibilities in the Preparation of Financial Statements ................... 19
AUGION sscmncncrenacsiwaensmesannaesnemaaeaanarenanen tamarNE TENEMENT THTTOa Terran 19
Statement as to disclosure of information to the aUCitOr .......... eeeeeeeee eee eeeeereeeeeeeeenee 19
ANNEXA...cececece cenceeen eeeeeeeeeeeeeeeeeeeeeeeeeneeeneeeenseeeeeeseeesseeeeessenssesssssesssseeseseeeseseeseesLO

Front cover image courtesy Findlay MacAskill, urology trainee, completing the Hackney Half Marathon for TUF.

----- Start of picture text -----
()
----- End of picture text -----

The Urology Foundation annual report & financial statements 2021

Chairman’s statement

Overview of the year

It was pleasing to see the charity able to make more awards and to support more urologists and researchers in 2021, compared with the previous year, in spite of the continuing impact of Covid-19 on our - operations. We are currently funding over 50 projects covering a range of urological diseases from prostate, kidney and bladder : »y) cancer to urinary tract infections and incontinence. This was ce largely due to our regular donors, and to Trusts & Foundations and é companies, many of whom share our mission of improving quality of life and outcomes and saving lives. Without their ongoing gi commitment and support our ability to make awards, meet our { Sif objectives and support the urology community would have been : oi more limited, particularly as opportunities to fundraise were still constrained due to Covid-19.

2021 saw The Urology Foundation making some significant investment into urological research and care, most notably the creation of our TUF Trials Unit. Following a competitive tendering process we signed a three year partnership with the Centre for Healthcare Randomised Trials centre in Aberdeen to encourage and enable more clinical research in urology. Trials are an important way of measuring a medical, surgical or behavioural intervention and successful trials are catalysts for change, provide potential for transformational discoveries and drive improvements in services. The role of the TUF Trials Unit is to identify promising and important research ideas from urology departments from all corners of the UK and provide a team of medical investigators to bring those ideas to fruition. This approach will enable more high-quality urology trials to take place, leading to better care, quicker recovery times and fewer long-term issues.

2021 also presaged some changes to the TUF team with our Chief Executive, Louise de Winter, saying she wished to step back into a part time role within the organization. We are hugely indebted to Louise for her leadership and commitment to TUF over the past decade. Since her tenure TUF has expanded its programmes and funding to provide many more opportunities for research and training, and also to include specific funding for urology nurses. So, we were thoroughly delighted that Louise expressed her wish to continue to contribute to TUF in a renewed capacity as Director of Research & Operations, as she remains deeply committed to the charity and looks forward to being a part of its ongoing future success.

We were very pleased to welcome Rebecca Porta as our new TUF CEO in January 2022. Rebecca has held senior roles within some of the UK’s leading health and medical research charities, and was Chief Executive of Orchid Cancer Appeal, the male cancer charity for over 11 years, responsible for driving transformation and growth including the introduction of Nurse-led Services, training for healthcare professionals and national media campaigns. We are confident she will build upon the excellent work and foundations that Louise has created and help us take The Urology Foundation to the next level.

Finally, it was a pleasure to connect in person with some of our donors and supporters at the TUF dinner hosted by TUF Patron, Jane MacQuitty at Vintners’ Hall last November. It provided a real boost to morale and a fantastic evening was had by all, with more funds raised to support our vital work. We will continue to put the needs of urology patients and the urology community of professionals at the heart of what we do.

Paul Fletcher, Chairman

----- Start of picture text -----
()
----- End of picture text -----

The Urology Foundation annual report & financial statements 2021

Objectives and Activities

The Urology Foundation’s objects are to:

“Advance, promote, encourage, develop and improve the study and knowledge of urology, urological surgery and the general knowledge of science and medicine and all matters relating to the progress and development of that branch of science and medicine and for that purpose to fund, aid, maintain and endow scholarships, fellowships, chairs and bursaries and generally to assist in the funding, instruction and support of persons and institutions engaged or involved in urological research work.”

Our Vision and Mission

We see a world where people will not die early from urological cancers and diseases, and where people with bladder, kidney and prostate problems can still lead full, active and productive lives.

Our mission is to improve survival and quality of life for urology patients through research and training, so patients receive the best possible treatment and care and fewer lives are devastated.

Our Aims

The Urology Foundation is committed to reducing the suffering caused by urological diseases. We work with researchers, urology and health care professionals to improve the diagnosis, treatment and management of urological disease and the nation’s urology care.

We rely on donations from individuals, trusts and foundations, and from companies to help fund our work. The money we raise is invested directly into research to find better treatments and cures, and in training for urology professionals to care for and help people affected by urology conditions.

The Foundation is governed by the rules and regulations set down in its company memorandum and articles of association originally dated 12 February 2009 and last updated by a special resolution on 29 June 2009.

Our Values

In undertaking our remit we are:

e Ambitious to see UK urology care, treatment and practice is the best in the world.
e Dedicated to beating all urology diseases through research and training.
e Proud of working in urology and committed to transforming the lives of people with a urology condition.
e Collaborative; working with researchers, urologists, nurses and health care professionals, influencers and decision makers, other charities, patients and their families we are improving the nation’s urology care.

What we do

We seek to improve patient treatment and care through investing in research and training. We fund research that increases our understanding of urological diseases and that can bring about change in urology practice and guidelines to the benefit of patients. We are also looking for ways that can make treatments more effective and kinder. We are driving improvement in standards in urology practice through training and we are developing the next generation of urological experts who can meet the challenge of the increased burden of disease and who put excellence of care at their core.

Our website provides information on the signs and symptoms of urological diseases and sets out some of the treatment options available. Our campaigns such as Urology Awareness Month in September bring urology conditions to the public eye, and focus on breaking the stigma of these diseases.

----- Start of picture text -----
()
----- End of picture text -----

The Urology Foundation annual report & financial statements 2021

Public Benefit

The trustees have taken The Charity Commission’s general guidance on public benefit into consideration in preparing their statements on public benefit contained within this trustees’ annual report. In accordance with its charitable objectives, The Foundation gives grants to individuals and not-for-profit organisations to:

e Promote the study of urological cancers and conditions by supporting and carrying out research into the causes, prevention, diagnosis and method of treatment of this disease and by publishing the useful results of such research;
e Provide opportunities for training and education of health professionals working in urology, in order to advance practice and improve patient treatment and care;
e Such other purposes for the benefit of the community as shall be exclusively charitable as the trustees from time to time shall decide.

In addition, TUF provides information on its website on urological cancers and conditions, and raises awareness through social media channels and media such as press and radio.

Grants policy

TUF advertises its programmes and awards on its website and through its professional e-newsletter. Applications for Research Scholarship funding are assessed by the SEC and the Reviewing Panel. Other applications for funding are assessed by the SEC.

TUF is a member of the Association of Medical Research Charities (AMRC) and abides by its standards and guidelines for peer review and funding. It is also a National Institute for Health Research (NIHR) non-commercial Partner. Research studies funded through TUF’s NIHR approved funding streams are automatically eligible for consideration for NIHR Clinical Research Network (CRN) support subject to meeting the standard study eligibility criteria.

()

The Urology Foundation annual report & financial statements 2021

Comparison of 2020 v 2021 An Overview

----- Start of picture text -----
|||||||||||||||| |---|---|---|---|---|---|---|---|---|---|---|---|---|---|---| |TOTAL WUMBER OF INDIVIDUALS|glade|aeeminesien|cries| |IOIRIECTILY|SlPIORITIED|BY TM|TUF GRANT FUNDING| |2020=10|2021|=16|2020=8|2021=15| |ee|8|@|8|®|¢|8|@| |, ,|yy|||rf|ft f|Gel teal ire|tens]|©|fftecn] nea|Tite] Ute| |Innovation“|ian) wre}|Pitt re|&ie|ResearchD)|faye|fe b=|rae|Awardsih|"A|ral|il|Ce|SMALL RESEARCH|PROJECTS| |TUF's|mission to work|accross|all|urology| |is|reflected|in the range of research|areas that we fund|the|amount| |awarded|for our| |2020|Ba|Pen ops|small|research|projects| |3|awards|Pelvic|Floor Materials| |£139,968|Posterior Urethral Valves| |AO?|Kidney Tumours| |azig,|awarasgps:|IncontinenceBladder- Sling Cancer Tensioning |Awarded|2020|:-|£29,800| |9296 50%|Kiban brea|Awarded|2021 - £39,737| |cans|Incontinence|-|Pelvic|Mesh| |*|Fumeskey|The Hesthuide|Trust| |TUF|UROLINK|FELLOWSHIPS| |3 yearinvestment|CG)|in 2021|we|awarded| |URoLoGY ()| |—|enabling|senior level trainees| |TUF TRIALS UNIT|to undertake training|in| |low|to|middle income|countries|

----- End of picture text -----

The Urology Foundation annual report & financial statements 2021

()

Achievements and Performance in 2021

1. Seeking better treatments and cures through research

With over 750,000 urology hospital care episodes each year in the UK, urology is a specialty faced with a high demand, yet the field remains remarkably under researched. While there have been notable successes in prostate cancer, much of urological practice lacks level one evidence to guide practice. Surgery in general, and urology in particular, currently attracts a disproportionately small proportion of clinical trials funding compared with the massive burden of urological diseases on NHS expenditure. Two key factors that have led to lack of trials are the complexity of surgical trials and the potentially hazardous and invasive nature of interventions.

We set out to address these challenges by creating an infrastructure to develop fund worthy urological trials by securing sufficient methodological expertise and support for good research ideas. Successful trials that go on to develop evidence for best practice and guidance on treatment of urological diseases will result in huge patient benefits. Our competitive call to work with an established Trials unit within the UK attracted responses from one third of all the units throughout the UK, leading us to set up the TUF Trials Unit in partnership with the Centre for Healthcare Randomised Trials (CHaRT) in Aberdeen.

TUF Trials Unit (TTU): in 2021 following a Dragon’s Den session to consider ideas for urological trials, two proposals have been taken forward by the TTU:

| Ei Urology trainee, Nikita Bhatt, Consultant urologist, Krishna 4 wants to investigate the use of Narahari, wants to assess the S ji | stents following stone surgery. clinical and cost effectiveness of yy uncomplicated telescopic stone (PLND) in high-risk prostate “ i. surgeryPatients undergoingroutinely have a stent cancerpelvic lymphsurgery. node dissection = he placed after their operation in The role of PLND in prostate a majority of the cases, despite guidelines stating cancer surgery has been controversial for the last 3 these may not be necessary. decades. Perceived benefits include optimal staging, Stents have a role in some cases but patients usually Mentitying caridatss (21 additional iNet pies ole find them bothersome, interfering with their daily possible better cancer control. Harms include higher aes Z : : : op time and complications such as blood loss, lymph activities and affecting their quality of life. In some collections requiring interventions and injury to cases they can cause harm. nerves and vessels. To date, there remains a distinct No previous trial has compared patients’ quality of | lack of evidence of benefit of PLND in prostate life with or without a stent after such a procedure, cancer. we Dente vant Sind oat it BiersA difference in The purpose of this clinically integrated pragmatic this that may change clinical practice. randomised multicentre UK trial is to address this evidence gap and inform surgical practice worldwide.

2021 also saw the introduction of our new funding stream, the Innovation & Research Award, replacing our previous Research Scholarships. The award funds projects up to a value of £60,000 that seek to use new, exciting, innovative approaches to address urological diseases and disorders. The projects must either (a) aim to create innovative treatments or devices, (b) aim to deliver innovative care pathways or (c) aim to use innovative research techniques or methods. It was gratifying that in its first year, the award attracted a high number of applications (19) from across the UK and a wide range of urological conditions.

Five projects were selected for funding:

Kidney tumours: There are approximately 13,000 new kidney cancer diagnoses in the UK each year, projected to rise by 26% by 2035. Due to increasing use of medical imaging, most kidney tumours are

----- Start of picture text -----
()
----- End of picture text -----

The Urology Foundation annual report & financial statements 2021

now detected incidentally at an early stage i.e. picked up on a scan done for another reason. However, not all lumps that grow in the kidney are cancer. As many as two in every ten growths found in the kidney incidentally are a non-cancerous. This project aims to evaluate existing and novel diagnostic imaging techniques in the assessment of small renal tumours, with a view to reducing unnecessary invasive diagnostics and management in patients with benign disease.

Kidney stones: Kidney stone disease is a common problem that affects ~20% of men and ~10% of women by 70 years of age. Unfortunately, up to 50% of individuals who have formed a kidney stone will form a second stone within 10 years of their first. Furthermore, individuals who recurrently form kidney stones are at increased risk of chronic kidney disease. The reasons why some people form kidney stones recurrently are poorly understood and the need for improved treatments is widely recognised. This project aims to understand associated genetic variants and identify drugs that have the potential to be innovative therapies for kidney stone prevention.

Bladder Cancer: Bladder cancer (BC) is the seventh most common cancer in the UK and is associated with increasing age and smoking. As the population ages rates of incidence will likely increase. The current gold standard for diagnosing BC is cystoscopy under local anaesthesia but this invasive procedure is associated with complications. This study will look at alternative ways of diagnosing BC through electrical analysis of cells in urine, and identify methods of tumour grading, ahead of a subsequent clinical trial.

Incontinence: The prevalence of Stress Urinary Incontinence (SUI) in women aged over 21 years in the UK has been reported to be 24%, with 9% of those considering it bothersome enough to want surgical treatment. This project aims to develop and validate a system that can be used to measure pressure along the urethra (waterpipe/bladder outlet) during surgery to treat stress urinary incontinence (SUI, leakage of urine during exercise, cough, sneeze or strain).

Pelvic Mesh implants: In pelvic mesh surgery, a sheet of material is permanently implanted to support pelvic organs that have shifted downwards into the vagina, or to treat the involuntary leaking of urine. Research suggests up to 30% of women experience long-lasting pelvic pain after pelvic mesh surgery. However, the current tools used to assess pain related to pelvic mesh implants have not been developed specifically for these patients. Therefore, our current understanding of the problem might be incomplete. To address this issue, the aim of this project is to develop a questionnaire that can be used to assess pain associated with pelvic mesh implants. In particular, the questionnaire could be used to assess outcomes following mesh removal procedures.

In 2021 our Small Research Projects fund, which is geared towards improving treatment and care, once again received a high level of applications in the first round (11). We had increased our budget for these awards in 2021 to accommodate four projects. The variety and quality of the applications were such that we were able to make all four awards from this tranche but sadly had to close the fund for the rest of the year. Awards were for the following projects:

e Accurate and timely detection of testicular torsion by urology registrars in training. e A pilot study into measuring urine flow remotely, to speed up diagnostic appointments and reduce waiting times.
e Research into BXO, a chronic and progressive inflammatory skin disease affecting the male external genitalia, causing deformities and considerable pain.
e Developing new measures for reporting male infertility trials, to ensure better treatments going forward.

In addition to the above grants and awards, we were also fortunate to receive funding from The Champniss Foundation and the Champniss Charitable Trust to fund a Cancer biomarker / wearable sensor study, to establish and test a repository for integrating genomic and wearable sensor data in order to explore a relation between the two and cancer outcomes. This study is being led by Professor John Kelly at University College London (see box).

----- Start of picture text -----
()
----- End of picture text -----

The Urology Foundation annual report & financial statements 2021

----- Start of picture text -----
Case study: Seeking better treatments and cures through research
----- End of picture text -----

Collecting and integrating genomic and wearable sensor data in order to explore a relation between the two and cancer outcomes.

Covid-19 has highlighted the need to be able to track post-operative cancer patients remotely for any signs of degradation in health or recurrence of cancer. Moving forwards, there will also be a desire to reduce unnecessary hospital appointments for the patient, if remote monitoring is effective and reliable.

There is a correlation between a patient’s physical activity and recurrence of cancer. Loss of activity is strongly associated with cancer specific survival in patients after radical cystectomy. An initial study in post-operative cancer patients wearing fitness trackers (eg Fitbits or similar) showed that loss of activity was detected prior to evidence of measurable disease on imaging, and suggests that there may be changes in activity at a very early stage of cancer recurrence. We now wish to combine this data with genomic changes in patients’ blood samples for evidence of cancer recurrence.

Taken together, the combined approach may well reveal markers for clinically relevant states such as disease recurrence and progression. Further, linkage between the genomic state and the activity state may highlight cases for additional therapies, and be a means to monitor response to therapy.

Improving knowledge and skills through training The impact of the pandemic on formal training continued during 2021 while the NHS struggled to cope with backlogs and staff shortages. Nevertheless, we launched our TUF/Urolink Fellowships which provide UK trainees opportunities to teach and train in low to middle income countries, and saw a take up in applications for trainees to supplement their training.

Support for urology trainees

The TUF/Urolink Fellowships is open to those senior level trainees who have completed their FRCS (Urol) and it is expected that the successful applicants will accompany established workshop teams in the first instance, and stay to work in that centre (or those centres) for an unspecified time after the workshop team’s departure. In 2021 three awards were made:

e Nishant Bedi from Barts Health NHS Trust e Patrick Gordon from St James Hospital Leeds e Su-Min Lee from Musgrove Park Hospital, Taunton

The destinations for each of the visits are still to be advised, and we hope they can take place in 2022.

The Keith Yeates Medal/Ralph Shackman prize is only conferred when candidates achieve over 90% in their Intercollegiate Specialty Examination in Urology. In 2021 two candidates made the grade: Ms Sophia Cashman and Mr Ben Starmer. They each receive a travelling fellowship worth £2,000. Due to ongoing travel restrictions at the time, they have yet to arrange their visits.

Support for urology nurses

Our planned Communications and Leadership Skills course for nurses, originally planned for 2020, had to be postponed yet again because of the pandemic. A date has now been set for 2022. Sadly, because of the ongoing pandemic and restrictions around travel, there were no applications for TUF travel grants for nurses in 2021. We hope this funding stream will pick up in 2022. TUF is liaising with

()

The Urology Foundation annual report & financial statements 2021

representatives of the British Association of Urological Nurses (BAUN) to support ongoing nurse training and education.

Improve public awareness of urological conditions and symptoms

The Urology Foundation has continued to build public awareness of urological cancers and conditions as well as raise the profile of urologists and urology nurses for better patient care. Our main channel for engaging with the public has been through our website, with visitor numbers spiking during Incontinence Week in June and during September Urology Awareness Month. The most visited pages continue to be those that provide health information on the male reproductive organs, Urinary Tract Infections (UTIs), kidney stones and bladder problems. The majority of website visitors are women (52%) but the highest number of users were in the 18 - 34 age range, comprising 44% of visitors to the site.

TUF’s social media profile is also growing with Facebook and Instagram more popular among the general public. Our Facebook user numbers have historically risen most around World Continence Week in June and Urology Awareness Month in September. Twitter and Linked-In have higher numbers of urology professionals engaging. During 2021, our Twitter followers increased by 10 per cent bringing the total number of followers to 4,436. The average numbers of people seeing each tweet is just shy of 1,200.

Our Urology Awareness Month in September focused on the need for people to be open about concerns and to get checked if worried about any symptoms; provided key information on signs to look out for and tips and advice for maintaining good urological health (examples below). We featured in key press such as the Journal of Clinical Nursing, and a Guardian Media Planet supplement, as well as providing content for online health forums and lifestyle websites such as ManDad Magazine.

----- Start of picture text -----
&AyrareniessUROLOGY ; keepingsigns wellof hydrateddehydrationUroroeyis vitalare visible for yourin urologyyour urine health
HAVE THE —_° ar | sin —
CONVERSATION siasone “ti “yp mre
o ryan aH range s Pinks Redes
of Keephydrat d w e ll 4e(Te)active
ry Can Fata i Awoid
ary healthy diet fits» alcoholere
Quitsmoking ggue Limitsalt intake your
----- End of picture text -----

We continued to partner with TalkHealth, an online health website, to provide information blogs and expert-led medical advice forums about urological health matters to members of the public, and to provide articles on urological health matters for supplements in national newspapers.

()

The Urology Foundation annual report & financial statements 2021

4. Plans for the future

The incidence of urological cancers and conditions is increasing, as is the prevalence of bladder and incontinence problems, benign prostate problems and kidney stones. This is leading to major morbidity and quality of life issues for urology patients and places a growing burden on the healthcare service, and on those working within it. Allied to this, the way in which healthcare is delivered will need to change, with an emphasis on personalised medicine and community-based services which are designed to enhance both patient outcomes and experience.

In 2021 we introduced two major new grant programmes, the TUF Trials Unit and our Innovation & Research Awards, and we were gratified to see such a positive response and so many applicants to these. We aim to ensure that more urology professionals from around the UK regions can benefit from the opportunities we offer, and we intend to create some regionally specific awards to facilitate access to our programmes.

In May 2021 our CEO, Louise de Winter, announced her intention to stand down and move to a part time role within the charity. She now has responsibility for our programmes and grants, and has plans for introducing a new system to make it easier for people to apply online for grants and for peer reviewers to comment. With over 50 active open grants, TUF needs a robust system for managing our grants and grant holders, and for keeping track of where the research we have sponsored leads.

Rebecca Porta joined the charity as CEO on 4 January 2022. Her appointment provides us with an opportunity to revisit our strategic goals and to ensure our programmes and activities align with the needs of urology patients and urology community. A key focus will be to ensure that going forward, we work with a wide range of stakeholders to drive change and improve the outlook for those affected by or interested in urology.

Given the impact of the pandemic we will look to diversify our income streams - this will include expanding our events programme, developing partnerships with the wider business community alongside strengthening existing relationships and investing in our marketing and communications programme. To this end there are plans to hold a strategy session in early 2022.

The key to meeting the many challenges of urological disease is to develop a cadre of top-quality urological professionals who have access to the very latest research developments and technological innovations, and who put excellence of care and continuous professional development at their core. We will develop research and training programmes with these outcomes, and the wellbeing and quality of life of patients, in mind.

The Urology Foundation annual report & financial statements 2021

()

Financial Review

Financial Results of Activities & Events

----- Start of picture text -----
Assets & Income: 2020 v 2021
£3,000,000
£2,500,000
£2,000,000
£1,500,000
£1,000,000
£500,000£0 iz EEE
Net Assets Voluntary income Event income
m 2020 m2021
----- End of picture text -----

The total value of net assets held by The Urology Foundation on 31 December 2021 was £2,447,884 (2020 £2,158,423). The Foundation’s fundraising activities and other initiatives during the course of 2021 generated a total of £686,522 of voluntary income (2020 £1,366,619) and a further £83,389 (2020 £64,920) from specific fundraising event income.

Fundraising

TUF continues to be wholly reliant on fundraised and donated income to fulfil its remit. The charity operates a mix of its own fundraising activities and those organised and undertaken by third parties on its behalf.

The ongoing uncertainty of Covid-19 continued to impact our fundraising, with our charity trek to Machu Picchu having to be postponed once again. However, our annual Bike4TUF cycle ride took place with a 250 mile ride through the north Cotswolds and Warwickshire, raising over £30,000. We are also grateful to a number of individual patients, supporters, urologists and trainees who undertook various fundraising challenges for TUF, raising over £7,800.

In November we were fortunate to be able to finally go ahead with our Wine Tasting Dinner and auction at Vintners’ Hall, with TUF Patron and The Times Wine Correspondent, Jane MacQuitty, as our host and guide to the wines. The evening raised £45,000 and it was clear that there was a real joy among guests at being able to be together in a room, rather than on a zoom screen.

However, once again a huge and special thanks must be paid to TUF’s ongoing supporters who donated throughout the year. The Foundation also received a number of significant donations from Trusts and Foundations and individuals, which did so much to enable our programmes and operations to continue throughout this difficult year. (See Annex A.)

Reserves & Liquidity Policy

The Foundation currently has ‘free reserves’ of £2,097,116 (31 December 2020: £1,675,542).

The Foundation’s policy is to maintain reserves sufficient to continue to fund its objectives on a long term basis, and to ensure that TUF operates with an adequate level of liquidity to (i) minimise the risk associated with a temporary or unforeseen shortfall in liquidity; (ii) manage its cash and

----- Start of picture text -----
()
----- End of picture text -----

The Urology Foundation annual report & financial statements 2021

investments to meet its liabilities and remain a going concern for at least 1 year in the event of an unplanned drop in income. Liquidity is defined as cash and the investment portfolio held as Unrestricted funds. The Policy establishes a minimum liquidity target for TUF of £500,000 (“Minimum Required Reserve”) subject to future modification by the Finance Committee and trustees’ approval.

The trustees consider that reserves held in excess of the amounts required to fund all future commitments together with the initial fund of £500,000, will be available to increase its visibility and expand its operations including funding for further research and a wider range of projects. The trustees plan levels of expenditure from unrestricted and restricted funds for the year ahead based upon the level of incoming resources for the current year as well as utilising restricted funds.

Statement of going concern

The Foundation’s unrestricted net funds generated in 2021 are judged to be sufficient to meet the requirements of the charity for charitable giving in the coming year.

Investments Policy

The Foundation’s investments are managed by Rothschild Bank (Cl) Limited. The Treasurer and the Chief Executive are responsible for managing the relationship with Rothschild but changes in investment strategy are subject to approval by the board of trustees. The investment manager is asked to attend at least one board meeting annually.

The board follows a medium risk ‘Balanced’ investment strategy which is intended to achieve steady growth over the long term through a diversified approach to investment. Capital preservation in real terms over a long term horizon is the primary objective and some volatility is acceptable in order to achieve this. TUF’s investments are held in the Exbury Fund, an ethical portfolio managed by Rothschild. The fund achieved a 14.5% return over 2021.

All other Foundation funds are held in accounts with the charity’s bankers, National Westminster Bank plc. In 2021 the charity closed its account with CCLA Investment Management Limited, and the balance of funds (c. £11,000) were transferred to the charity’s NatWest bank account.

Remuneration policy

In setting salary levels, The Urology Foundation follows the National Council for Voluntary Organisation’s advice that a charity’s pay policy should be to offer fair pay to attract and keep appropriately-qualified staff to lead, manage, support and/or deliver the charity’s aims. It also conducts online research of charity salaries and uses surveys to benchmark levels of pay. The Urology Foundation does not automatically award its staff with annual salary increases, either incremental or cost of living.

Pensions policy

The charity offers a stakeholder pension, operated by The People’s Pension (B&CE Holdings), in line with statutory requirements. All new staff are automatically enrolled but can opt out if desired.

Equal opportunities and diversity policy

TUF is committed to being an Equal Opportunities employer and to respecting diversity, and is determined to ensure that no job applicant, employee, or trustee receives less favourable treatment on the grounds of their age, disability, gender reassignment, marriage and civil partnership, pregnancy or maternity, race, religion or belief, sex or sexual orientation. TUF also seeks to ensure that its employees are not victimised or subjected to harassment.

The policy applies to recruitment and selection for jobs in the Foundation, career development and training, promotion and transfer, performance management, pay, redundancy, disciplinary and grievance procedures, the application of terms and conditions of employment and any other aspects of employment with the Foundation.

()

The Urology Foundation annual report & financial statements 2021

al!

The policy also applies to third parties such as trustees and committee volunteers, clients (ie grant applicants) and suppliers.

Principal risks and uncertainties

The trustees take the management of risks seriously. The Chairman of the board of trustees and the Chief Executive are charged with responsibility to ensure that the risks which have been identified are adequately assessed and properly mitigated on a regular basis. The potential risks have been discussed with the Chairman and the charity and a formal risk register is kept and brought before the board on at least an annual basis.

Impact of Covid-19 and war in Ukraine

The pandemic continued to affect the urology workforce, which meant that applications to some of our programmes - mainly travel and fellowship grants - remained low. However, our applications for research grants were not impacted, and we also saw some pickup in activity with researchers returning to labs. Looking forward, the ongoing war in Ukraine has broader economic implications, some of which will be reflected in our investment fund holdings. Our Investment Manager keeps us regularly updated and there is no immediate cause for concern or action.

Risks to Data

The charity takes its responsibilities for data very seriously. We follow a Data Protection policy based on the GDPR and have a nominated trustee (Mr Adrian Joyce) who has Board oversight for data compliance. We use a professional data base provider that stores all information in the cloud and this is secured using a two-step password verification. We review our records on an ongoing basis and delete old or historical records that are no longer relevant, and remove people who no longer wish to hear from us (provided that there is no financial information that we need to retain).

Other key risks are assessed as follows:

Governance	Impact of the external environment on fundraising, in particular: public
/Environmental	confidence in charities; new fundraising regulations; Data Protection
	Regulations.
Income Sources	TUF is wholly reliant upon voluntary income as an annual source of funding.
	It is the role of the trustees to manage risk exposure on fundraising activities
	and in doing so to accept an appropriate level of risk in order to raise income
	from a wide range of sources.
Risk of data	The charity uses a professional database provider that stores all information
breach	in the cloud and this is secured using a two-step password verification. TUF
	also regularly deletes any old or historical records that are no longer relevant.
	The charity’s own day to day working documents are also stored on a cloud-
	based system. We believe that keeping data in the cloud is still safer than
	keeping it on our own servers. TUF staff are regularly made aware of possible
	phishingscams and to be alert toany potential email orsystem data breaches.
Key Person risk	The small staff base makes TUF heavily reliant on the Chief Executive and a
	few key trustees so the unexpected loss or departure of the Chief Executive
	or certain trustees is a risk. Succession planning processes have been
	identified as necessary going forward.
Investment Risk	TUF’s success is directly related to the amount of resource it can devote to
	its objectives, so the key risk identified by trustees relates to the proper
	management of its funds. Imprudent or unprofessional decisions could
	majorly impact on the performance of those funds. In common with similar
	charities, TUF employs professional fund managers, whose performance is
	regularly reviewed by the Treasurer together with other trustees.
Risk to Employees	Employees are not subject to risks other than those likely to be associated
	withroutineofficework.ApartfromobtainingstatutoryEmployersLiability

The Urology Foundation annual report & financial statements 2021 ()

Insurance, TUF nonetheless treats the welfare of its staff as a priority. The Chief Executive is the Nominated Safety Officer for the purposes of the Health and Safety at Work Act. The premises are checked and maintained by the landlord and by the fire service to ensure appropriate mitigation of the risk of fire. Employees are aware of the location of fire extinguishers. The charity also has a number of policies in place covering Equal Opportunities, Lone Working, Working from Home and Safe Guarding Vulnerable People. Risk that research | Grants awarded are subject to rigorous review by the SEC and Reviewing fails to deliver | Committee. Grantees are expected to submit progress reports and these are results reviewed by the SEC and TUF. The charity maintains ongoing communication with grant holders. Loss of Records To protect against the loss of records, and to increase data security, files are stored in the cloud. The risk of any unsaved data being critical to TUF is regarded as insignificant. Other similar risks are dealt with by insurance.

The Urology Foundation annual report & financial statements 2021

()

Structure, Governance & Management

The Urology Foundation is a charity and a company limited by guarantee and was established on 12 February 2009 to incorporate the charitable activities of the British Urological Foundation (BUF), an unincorporated charitable trust established in 1994 by the British Association of Urological Surgeons and BJU International, and a registered charity since 17 March 1995. The Urology Foundation itself became a registered charity on 19 March 2009.

Charity Governance Code

The Board and Executive of the charity abide by the standards set by the Charity Governance Code when executing their duties. The overall strategic direction of the charity is determined by the trustees, who meet three times each year including an Annual General Meeting.

Trustee Recruitment, Training and Induction

The Foundation seeks to achieve a balance of lay and medical trustees. Appointed trustees are recruited on the basis of fulfilling the criteria to provide a balance of experience and knowledge. Members of the charity’s Scientific and Education Committee (see below) are recruited through calls in industry publications.

All new trustees are provided with a face-to-face induction meeting and an induction pack. They are provided with relevant Charity Commission publications and regularly briefed on developments and opportunities that will support their general understanding of the voluntary sector, healthcare and medical research issues.

Appointment & Election

The Trustees and Chairman are appointed for an initial period of three years that can be extended for a further three-year term. A further extension may be made if it is deemed to be in the best interests of the Charity. The governing document requires that there should be a minimum of seven trustees.

Two of the trustees are required to be representative trustees, one nominated by The British Association of Urological Surgeons (“BAUS”) and one nominated by British Journal of Urology International (“BJUI”). All other trustees, known as appointed trustees, are appointed by unanimous written resolution of all the trustees present and/or voting at a special meeting of trustees called to take place immediately before or after an ordinary meeting of trustees.

The representative trustee nominated by BAUS is the President of BAUS and his appointment to the board is concurrent with his post at BAUS, which is for a period of two years.

The Executive Team

The Chief Executive, is responsible for the day-to-day management of the charity. She is assisted by a Director of Research & Operations and a Fundraising & Events Manager.

The Chief Executive deals with the implementation of policy and strategic decisions taken by the board of trustees. She and the appropriate staff members attend the meetings of the board of trustees and of all sub-committees, and report on the day-to-day operations of the charity. The Foundation currently operates the following sub-committees:

Scientific and Education Committee (SEC)

The SEC is responsible for the development and assessment of The Foundation’s research, education and training programmes and the review and administration of The Foundation’s grant making policy. The Chairman of the SEC, Professor Grant Stewart, is a member of the board of trustees, and reports back to the board on the work of the Committee. The SEC is made up of clinical and academic urologists and scientists with an interest in urology, and lay representatives. The BAUS Surgical

() The Urology Foundation annual report & financial statements 2021

Specialty Lead also sits on the SEC, ex officio, to provide further insight into the research and training needs of the profession.

Research Scholarship Review Panel

The Research Scholarship Review Panel is responsible for assessing applications for TUF’s major research grants and marking these according to the requisite criteria being met. In this task it assists the SEC in its final decision on who should receive grants. The Research Scholarship Review Panel is made up of clinical trustees and academic urologists and scientists with an interest in urology.

Membership of the SEC and Review Panel can be viewed on the charity’s website: https: //www.theurologyfoundation.org/about-us/who-we-are/our-team/committees. They provide their services as volunteers and TUF is enormously grateful to them.

Finance Committee

The charity Finance Committee is chaired by the Treasurer, Ms Angela Daniel. Membership includes The Chairman of the Board and the Chairman of the SEC, and two other trustees: Mr Becker & Mr Nicol, the Chief Executive and the Director of Research & Operations. Any recommendations made by the Finance Committee are brought to the board of trustees for discussion and ratification. The Treasurer has oversight of the charity’s bank and investment accounts.

Relationships with Related Parties

The Urology Foundation continues to maintain close links with its two founding charities, The British Association of Urological Surgeons (BAUS) and the BJU International, whose representatives are trustees. TUF is also represented on BAUS Council by trustee, Mr Ben Challacombe.

Representation on Other Bodies

The charity is a member of the Association of Medical Research Charities (AMRC), which confers a quality mark for TUF’s peer review processes, as well as advocating for charity-funded research with government. The Urology Foundation is a National Institute for Health Research (NIHR) noncommercial Partner. This means the studies that we fund may be eligible to access the NIHR Study Support Service which is provided by the NIHR Clinical Research Network. In 2022, TUF became a member of Cancer 52, a collaborative voice for rare and less common cancers and a member of the National Council for Voluntary Organisations.

The Urology Foundation annual report & financial statements 2021

()

Reference and administrative details

The registered charity name is “The Urology Foundation” (sometimes referred to as “TUF”), a charity and a company limited by guarantee.

Trustees

Mr Paul Fletcher (Chair) Ms Angela Daniel (Treasurer) Mr Mark Becker (Secretary) Prof Grant Stewart (Chair, SEC) Mr Ben Challacombe Ms Mary Garthwaite Mr Adrian Joyce Prof Alan McNeill (BJU! rep, appt Feb 2022) Mr Roland Morley Mr David Nicol Mr Tim O’Brien (BAUS rep) Prof Krishna Sethia (BJUI rep, retd Oct 2021) Ms Hannah Warren

President Prof Roger Kirb rormoger Ny

Patrons Mr Handel Evans Sir Ranulph Fiennes OBE Mrs Rosemary Macaire Ms Jane Macquitty MBE Mr Steven Norris

Ambassadors Mr Alex Corbisiero Mr Stephen Fry Mrs Kate Holmes

Chief Executive Ms Rebecca Porta (appt 4 January 2022)

Registered Office 1-2 St Andrew’s Hill London EC4V 5BY

Charity number 1128683 (England & Wales) Bonn nner mone 06817868 queers em Sie). eve Woodlands Grange, Woodlands Lane BradleyBristol BS32 Stoke4JY Bankers National Westminster Bank plc PO Box 2021 10 Marylebone High Street London W1A 1FH

Investment Manager Rothschild Bank (Cl) Limited St. Julian’s Court, St. Julian’s Avenue St. Peter Port Guernsey GY1 3UA

The Urology Foundation annual report & financial statements 2021

Trustees’ & Directors’ Responsibilities in the Preparation of Financial Statements

The trustees (who are also the directors of The Urology Foundation for the purposes of company law) are responsible for preparing the trustees’ Annual Report and the financial statements in accordance with applicable law and United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice).

Company law requires the trustees to prepare financial statements for each financial year which give a true and fair view of the state of affairs of the charitable company as at the balance sheet date, and of the incoming resources and application of resources, including income and expenditure, for that period. In preparing those financial statements, the trustees and directors are required to:

e select suitable accounting policies and then apply them consistently;
e observe the methods and principles in the Charities SORP;
e make judgements and estimates that are reasonable and prudent;
e state whether applicable UK Accounting Standards have been followed subject to any material departures disclosed and explained in the financial statements; and
e prepare the financial statements on the going concern basis unless it is inappropriate to presume that the charitable company will continue in business.

The trustees are responsible for keeping proper accounting records, which disclose with reasonable accuracy at any time the financial position of the charitable company and enable them to ensure that the financial statements comply with Companies Acts 2006. They are also responsible for safeguarding the assets of the charitable company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

The trustees are responsible for the maintenance and integrity of the corporate and financial information included on the charitable company’s website. Legislation in the United Kingdom governing the preparation and dissemination of financial statements may differ from the legislation in other jurisdictions.

Auditor

Mr Matthew Dobbins (FCA), of Dunkley & Co Ltd. has agreed to act as Auditor.

Statement as to disclosure of information to the auditor

The trustees and directors at the date of approval of this trustees’ annual report confirm that so far as each of them is aware, there is no relevant information of which the charity’s auditor is unaware, and the trustees and directors have taken all steps that they ought to have taken to make themselves aware of any relevant information and to establish that the auditor is aware of that information.

LaudFietther__

Paul Fletcher, Chairman

Date: Sep 20, 2022

The Urology Foundation annual report & financial statements 2021

Annex A

The Urology Foundation is extremely grateful to the following Trusts & Foundations and organisations who kindly supported our work in 2021:

Amelia Chadwick Trust Arbuthnott Charitable Trust Berni Charitable Trust Charles Reynolds Fund Dennis Byrne Charitable Trust Florence Shute Millennium Trust Girdlers’ Company Heathside Charitable Trust Hudson Charitable Trust Irving Memorial Trust Lord Belstead Charitable Trust Masonic Charitable Foundation Penguins Against Cancer Peter Stebbings Charitable Trust PF Charitable Trust Sidney Jason Charitable Trust The Hadley Trust The Manet Trust The Rosetrees Trust The Thompson Family Charitable Trust Yardley SBH Trust

We are also grateful to the following companies and their staff who donated in 2020:

Bank of England Court Award CJ Medical Ginmeister Ltd Intuitive Surgical Pelicans Manufacturing Co Ltd Santander Solutions PT WPA Health Yandell Publishing

Thank you to all our donors, fundraisers, supporters and volunteers who have made The Urology Foundation’s work possible.

The Urology Foundation annual report & financial statements 2021

()

Report of the Independent Auditors to the Trustees of The Urology Foundation (Registered number: 06817868)

Opinion

We have audited the financial statements of The Urology Foundation (the ‘charitable company’) for the year ended 31 December 2021 which comprise the Statement of Financial Activities, the Balance Sheet, the Cash Flow Statement and notes to the financial statements, including a summary of significant accounting policies. The financial reporting framework that has been applied in their preparation is applicable law and United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice).

In our opinion the financial statements:

give a true and fair view of the state of the charitable company's affairs as at 31 December 2021 and of its incoming resources and application of resources, including its income and expenditure, for the year then ended;
have been properly prepared in accordance with United Kingdom Generally Accepted Accounting
Practice; and : have been prepared in accordance with the requirements of the Companies Act 2006.

Basis for opinion

We conducted our audit in accordance with International Standards on Auditing (UK) (ISAs (UK)) and applicable law. Our responsibilities under those standards are further described in the Auditors’ responsibilities for the audit of the financial statements section of our report. We are independent of the charitable company in accordance with the ethical requirements that are relevant to our audit of the financial statements in the UK, including the FRC's Ethical Standard, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Conclusions relating to going concern

In auditing the financial statements, we have concluded that the trustees’ use of the going concern basis of accounting in the preparation of the financial statements is appropriate. Based on the work we have performed, we have not identified any material uncertainties relating to events or conditions that, individually or collectively, may cast significant doubt on the charitable company’s ability to continue as a going concern for a period of at least twelve months from when the financial statements are authorised for issue.

Our responsibilities and the responsibilities of the trustees with respect to going concern are described in the relevant sections of this report.

Other information

The trustees are responsible for the other information. The other information comprises the information included in the Annual Report, other than the financial statements and our Report of the Independent Auditors thereon. Our opinion on the financial statements does not cover the other information and, except to the extent otherwise explicitly stated in our report, we do not express any form of assurance conclusion thereon. In connection with our audit of the financial statements, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the audit or otherwise appears to be materially misstated. If we identify such material inconsistencies or apparent material misstatements, we are required to determine whether this gives rise to a material misstatement in the financial statements themselves. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact. We have nothing to report in this regard.

Matters on which we are required to report by exception

We have nothing to report in respect of the following matters where the Charities (Accounts and Reports) Regulations 2008 requires us to report to you if, in our opinion:

the information given in the Report of the Trustees is inconsistent in any material respect with the

financial statements; or

the charitable company has not kept adequate accounting records; or
the financial statements are not in agreement with the accounting records and returns; or
we have not received all the information and explanations we require for our audit.

The Urology Foundation annual report & financial statements 2021

Report of the Independent Auditors to the Trustees of The Urology Foundation (Registered number: 06817868)

Responsibilities of trustees

As explained more fully in the Statement of Trustees’ Responsibilities, the trustees (who are also the directors of the charitable company for the purposes of company law) are responsible for the preparation of the financial statements and for being satisfied that they give a true and fair view, and for such internal control as the trustees determine is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, the trustees are responsible for assessing the charitable company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the trustees either intend to liquidate the charitable company or to cease operations, or have no realistic alternative but to do so.

The Urology Foundation annual report & financial statements 2021

Report of the Independent Auditors to the Trustees of The Urology Foundation (Registered number: 06817868)

Our responsibilities for the audit of the financial statements

We have been appointed as auditors under Section 144 of the Charities Act 2011 and report in accordance with the Act and relevant regulations made or having effect thereunder.

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue a Report of the Independent Auditors that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs (UK) will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements. Irregularities, including fraud, are instances of non-compliance with laws and regulations. We design procedures in line with our responsibilities, outlined above, to detect material misstatements in respect of irregularities, including fraud. The extent to which our procedures are capable of detecting irregularities, including fraud is detailed below:

Extent to which the audit was considered capable of detecting irregularities, including fraud

We identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, and then design and perform audit procedures responsive to those risks, including obtaining audit evidence that is sufficient and appropriate to provide a basis for our opinion.

Identifying and assessing potential risks related to irregularities

In identifying and assessing risks of material misstatement in respect of irregularities, including fraud and non-compliance with laws and regulations, we considered the following:

The nature of the charitable sector, control environment and performance including the design of the organisation's remuneration policies;
Any matters we identified, having obtained and reviewed the organisation's documentation of their policies and procedures relating to:

o Identifying, evaluating and complying with laws and regulations and whether they were aware of any instances of non-compliance;

o Detecting and responding to the risks of fraud and whether they have knowledge of any actual, suspected or alleged fraud;

o The internal controls established to mitigate risks of fraud or non-compliance with laws and regulations;

o The matters discussed among the audit engagement team regarding how and where fraud might occur in the financial statements and any potential indicators of fraud.

As a result of these procedures, we considered the opportunities and incentives that may exist within the organisation for fraud and identified the greatest potential for fraud in the areas of management override of controls, going concern, income recognition, and the appropriateness of expenditure.

We also obtained an understanding of the legal and regulatory framework that the organisation operates in, focusing on provisions of those laws and regulations that had a direct effect on the determination of material amounts and disclosures in the financial statements.

Audit response to risks identified

Our procedures to respond to risks identified included the following:

Enquiring of management, concerning actual and potential litigation and claims;
Substantive testing to vouch source records to the financial statements;
Performing analytical procedures to identify any unusual or unexpected relationships that may indicate risks of material misstatement due to fraud;

The Urology Foundation annual report & financial statements 2021

Report of the Independent Auditors to the Trustees of The Urology Foundation (Registered number: 06817868)

Enquiring of management the internal controls in, evaluating each control for weakness and vouching to evidence of the control taking place;
In addressing the risk of fraud through management override of controls, testing the appropriateness of journal entries and other adjustments; assessing whether the judgements made in making accounting estimates are indicative of a potential bias; and evaluating the business rationale of any significant transactions that are unusual or outside the normal course of business.

We also communicated relevant identified laws and regulations and potential fraud risks to all engagement team members, and remained alert to any indications of fraud or non-compliance with laws and regulations throughout the audit.

A further description of our responsibilities for the audit of the financial statements is located on the Financial Reporting Council's website at www. frc.org.uk/auditorsresponsibilities. This description forms part of our Report of the Independent Auditors.

Use of our report

This report is made solely to the charitable company's trustees, as a body, in accordance with Part 4 of the Charities (Accounts and Reports) Regulations 2008. Our audit work has been undertaken so that we might state to the charitable company's trustees those matters we are required to state to them in an auditors’ report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the charitable company and the charitable company's trustees as a body, for our audit work, for this report, or for the opinions we have formed.

—_—

Dunkley's Chartered Accountants Registered Auditors Eligible to act as an auditor in terms of Section 1212 of the Companies Act 2006 Woodlands Grange Woodlands Lane Bradley Stoke Bristol BS32 4JY DCO ccssscccssarsscorrstaresneraranotonetnetarefocrearemonreniennnomnntsistatenSep 21, 2022

The Urology Foundation annual report & financial statements 2021

THE UROLOGY FOUNDATION

STATEMENT OF FINANCIAL ACTIVITIES

for the year ended 31 December 2021

		Unrestricted	Restricted	Total	Total
		Funds	Funds	2021	2020
	Note	£	£	£	£
INCOME
Donations and legacies	1	639,590	46,932	686,522	1,366,619
Other trading activities	2	83,389	-	83,389	64,920
Investments	3	41,020	-	41,020	653
TOTAL INCOME		763,999	46,932	810,931	1,432,192
EXPENDITURE
Raising Funds
Donations and legacies	4	42,022	4,665	46,687	51,864
Trading activities	5	21,262	2,358	23,620	22,612
Investment management costs		72	-	72	365
Expenditure on Charitable activities
Raising Awareness	6	77,315	8,575	85,890	88,885
Grant making	7	614,398	128,530	742,928	1,068,277
Net (Gains) on investment assets	11	(377,255)	(472)	(377,727)	(360,241)
TOTAL EXPENDITURE		377,814	143,656	521,470	871,761
NET INCOME/(EXPENDITURE)		386,185	(96,724)	289,461	560,431
RECONCILIATION OF FUNDS
Fund balances brought forward
at 1 January 2021		1,675,542	482,881	2,158,423	1,597,992
Transfer between funds		35,389	(35,389)	-	-
FUND BALANCES CARRIED
FORWARDAT31DECEMBER2021		2,097,116	350,768	2,447,884	2,158,423

The net movement in funds for the year arises from the charity's continuing operations.

No separate statement of total changes in equity has been presented as all such gains and losses have been dealt with in the statement of financial activities.

The notes on pages 29 to 39 form part of these accounts

The Urology Foundation annual report & financial statements 2021

THE UROLOGY FOUNDATION

STATEMENT OF FINANCIAL ACTIVITIES

for the year ended 31 December 2020 (Full fund comparative)

		Unrestricted	Restricted	Total
		Funds	Funds	2020
	Note	£	£	£
INCOME
Donations and legacies	1	515,235	851,384	1,366,619
Other trading activities	2	64,920	.	64,920
Investments	3	653	-	653
TOTAL INCOME		580,808	851,384	1,432,192
EXPENDITURE
Raising Funds
Donations and legacies	4	35,877	15,987	51,864
Trading activities	5	20,350	2,262	22,612
Investment management costs		365	-	365
Expenditure on Charitable activities
Raising Awareness	6	79,994	8,890	88,884
Grant making	7	378,014	690,263	1,068,277
Net (Gains) on investment assets	11	(359,687)	(554)	(360,241)
NET INCOME/(EXPENDITURE)		154,913	716,848	871,761
NET (EXPENDITURE)		425,895	134,536	560,431
RECONCILIATION OF FUNDS
Fund balances brought forward
at 1 January 2020		1,249,647	348,345	1,597,992
Transfer between funds		-	-	-
FUND BALANCES CARRIED
FORWARDAT31DECEMBER2020		1,675,542	482,881	2,158,423

The net movement in funds for the year arises from the charity's continuing operations.

No separate statement of total changes in equity has been presented as all such gains and losses have been dealt with in the statement of financial activities.

The notes on pages 29 to 39 form part of these accounts

The Urology Foundation annual report & financial statements 2021

THE UROLOGY FOUNDATION

BALANCE SHEET

as at 31 December 2021

Company Number 06817868

		2021	2020
	Note	£	£
FIXED ASSETS
Tangible assets	10	3,627	1,818
Investments	11	3,657,270	3,595,733
		3,660,897	3,597,551
CURRENT ASSETS
Debtors	12	98,723	77,773
Cash at bank and in hand		238,420	217,109
		337,143	294,882
LIABILITIES: amounts falling due within one year	13	1,133,522	1,238,761
NET CURRENT LIABILITIES		(796,379)	(943,879)
LIABILITIES: amounts falling due in more than one year	13	416,634	495,249
NETASSETS		2,447,884	2,158,423
THE FUNDS OF THE CHARITY
Restricted income funds	15
Robotic Surgery Training Fund		200,076	196,287
Prostate Cancer Research Fund		138,804	103,370
Bladder Cancer Fund		(31,425)	149,860
Travel Fellowship Fund		653	652
‘EQUIP’ Quality & Safety Pilot		-	30,889
Team Corbs - Testicular		2,158	1,823
Charles Reynolds		40,503	-
Unrestricted income funds	15
General Fund		1,597,116	1,139,859
Designated Fund (Ralph Shackman)		:	35,683
Designated Fund (British Urology Foundation)		500,000	500,000
TOTALCHARITYFUNDS	16	2,447,884	2,158,423

These financial statements have been prepared in accordance with the special provisions of Part 15 of the Companies Act 2006 relating to small charitable companies and with the Financial Reporting Standard 102.

The financial statements on pages 25 to 28 were approved by the trustees and authorised for issue on Sep 20, 2022 and are signed on their behalf by

----- Start of picture text -----
visti Chairman Missin aeteisicoiens NVCGSUNEL
Paul Fletcher Angela Daniel
Sep 20, 2022 Sep 20, 2022
----- End of picture text -----

The notes on pages 29 to 39 form part of these accounts

The Urology Foundation annual report & financial statements 2021

yay

THE UROLOGY FOUNDATION

STATEMENT OF CASHFLOWS as at 31 December 2021

		2021	2020
	Note	£	£
CASH FLOWS FROM OPERATING ACTIVITIES:	14
Net cash used in operating activities		(333,651)	973,271
Cash flows from investing activities:
Dividends and interest from investments		41,002	291
Management fees paid from investments		(72)	(365)
Purchase of equipment		(2,159)	-
Transfer from cash		-	(1,045,830)
Proceeds from sale of investments		852,452	1,162,282
Purchase of investments		(536,261)	(1,161,969)
Net cash used in investing activities:		354,962	(1,045,591)
Change in cash and cash equivalents in the reporting period		21,311	(72,320)
Cash equivalents at the beginning of the reporting period		217,109	289,429
Cashandcashequivalentsattheendofthereportingperiod		238,420	217,109

The notes on pages 29 to 39 form part of these accounts

The Urology Foundation annual report & financial statements 2021

THE UROLOGY FOUNDATION

Financial statements for the year ended 31 December 2021

ACCOUNTING POLICIES

BASIS OF ACCOUNTING

The financial statements have been prepared under the historical cost convention with items recognised at cost or transaction value unless otherwise stated in the relevant notes to these accounts. The financial statements have been prepared in accordance with the Statement of Recommended Practice: Accounting and Reporting by Charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) issued on 1 January 2019 and Financial Reporting Standard applicable in the United Kingdom and Republic of Ireland (FRS 102) and Charities Act 2011. The trust constitutes a public benefit entity as defined by FRS 102.

INCOME

Grants, donations and other similar types of voluntary income are brought into account when it is probable that they will be received, except that donated income is included gross of any attributable tax recoverable, where relevant. Donations given for specific purposes are treated as restricted income. Tax recoverable is recognised when claims are submitted to HM Revenue and Customs. Legacy gifts are recognised in the period in which the Charity becomes entitled to receive the income.

Income receivable from activities for generating funds and from investment income is accounted for on an accruals basis. Deferred income represents revenues collected but not earned as of 31 December 2021. This is primarily composed of income collected in advance of a fundraising event taking place and deferred until the charity is entitled to that income as and when the event takes place.

EXPENDITURE

Resources expended are allocated to the costs of generating funds or to the charity's principal activity where the costs can be identified as being directly related. All other costs are categorised as either support costs or governance costs, and are allocated in proportions based upon a suitable ratio applicable to the nature of the cost involved.

Grants payable are recognised in full in the period in which the approved offer is conveyed to the recipient. Grants are recognised and deferred where there is a long term commitment for the Charity. Where grants are recognised and conditions for staged grant payments are not met in subsequent years, an adjustment to grants payable will be made in the relevant accounting period. Expenditure includes irrecoverable VAT which is reported as part of the expenditure to which it relates.

TANGIBLE FIXED ASSETS

All tangible assets purchased that have an expected useful economic life that exceeds one year are capitalised and classified as fixed assets. Tangible fixed assets are stated at historical cost less depreciation. Depreciation is provided on all tangible fixed assets at rates calculated to write each asset down to its estimated residual value evenly over its expected useful life, as follows:

Office equipment

25% reducing balance

OPERATING LEASES

Rentals under operating leases are charged to the Statement of financial activities on a straight line basis over the lease term.

The Urology Foundation annual report & financial statements 2021

THE UROLOGY FOUNDATION

Financial statements for the year ended 31 December 2021

ACCOUNTING POLICIES

INVESTMENTS

The charity's investments are included in the balance sheet at their market value. The gains or losses arising upon their annual revaluation are included in the statement of financial activities.

FUND ACCOUNTING

The general fund comprises the accumulated surpluses of unrestricted incoming resources over resources expended, which are available for use in the furtherance of the general objective of the charity.

Designated funds are a particular form of unrestricted funds consisting of amounts, which have been allocated or designated for specific purposes by the trustees. The use of designated funds remains at the discretion of the trustees.

Restricted funds are funds subject to specific conditions imposed by donors. The purpose and use of the restricted funds are set out in the notes to the accounts. Amounts unspent at the year end are carried forward in the balance sheet.

FOREIGN EXCHANGE

Receipts and payments which occur in foreign currencies are included in the accounts at the amount into which they are converted in sterling, using the exchange rate on the day in which the transaction occurs.

GOING CONCERN

The Trustees as Directors of the Charity believe that there are no material uncertainties that may cast significant doubt about the ability of the Charity to continue as a going concern, due to the significant unrestricted reserves as at 31st December and the forecast income expected in 2022. As we prepare this statement in early 2022, it is clear that the long tail of the COVID-19 pandemic, and its impact on the NHS workload, continues to have a bearing on the charity’s operations, with applications for programmes such as fellowships and travel grants still low. It remains to be seen whether our events fundraising and income will be impacted by global issues such as the war in Ukraine and the current cost of living crisis, which may affect future budgets for research and training. The trustees believe, however, that given the level of available cash and reserves, the charity can continue as a going concern.

FINANCIAL INSTRUMENTS

The charity only has financial assets and financial liabilities of a kind that qualify as basic financial instruments. Basic financial instruments are initially recognised at transaction value and subsequently measured at their settlement value with the exception of bank loans which are subsequently measured at amortised cost using the effective interest method.

The Urology Foundation annual report & financial statements 2021

THE UROLOGY FOUNDATION

NOTES TO THE FINANCIAL STATEMENTS for the year ended 31 December 2021

		Unrestricted	Restricted
		funds	funds	2021	2020
		£	£	£	£
1.	INCOME FROM DONATIONS AND LEGACIES
	Grants received from charitable trusts
	and corporate sponsors	430,662	46,700	477,362	1,190,163
	Donations	204,348	232	204,580	162,456
	Legacies	4,580	-	4,580	14,000
		639,590	46,932	686,522	1,366,619
2.	INCOME FROM OTHERTRADING ACTIVITIES
	Income from fundraising events	83,389	-	83,389	64,920
3.	INVESTMENT INCOME
	Bank interest receivable on short
	term cash deposits	18	-	18	362
	Income from investments listed on
	a recognised stock exchange:
	UK investments	41,002	-	41,002	291
	Overseas investments	-	-	-	-
		41,020	-	41,020	653
4.	COSTS OF RAISING FUNDS
	VOLUNTARY INCOME
	Direct costs	25,398	2,822	28,220	30,191
	Support costs (see note 8)	16,624	1,843	18,467	21,673
		42,022	4,665	46,687	51,864

The Urology Foundation annual report & financial statements 2021

THE UROLOGY FOUNDATION

NOTES TO THE FINANCIAL STATEMENTS for the year ended 31 December 2021

				Unrestricted	Restricted	Restricted
				funds		funds	2021	2020
				£		£	£	£
5.	COSTS OF RAISING FUNDS
	TRADING ACTIVITIES
	Costs of fundraising events			4,638		515	5,153	939
	Support costs (see note 8)			16,624		1,843	18,467	21,673
				21,262		2,358	23,620	22,612
6.	COSTS OF RAISING AWARENESS
	Costs of fundraising events			10,821		1,203	12,024	2,190
	Support costs (see note 8)			66,494		7,372	73,866	86,695
				77,315		8,575	85,890	88,885
if	GRANT MAKING
	Research Scholarships awarded to			295,939		(32,051)	263,888	120,950
	5 (2020: 3) individuals
	[Cancerbiomarker/wearablesensorstudy Small Research Projects				=	180,000	29,738
	awarded to 4 (2020: 3) teams
	7.17%	- 7,176	__15,000	4,500	- 4500	-_—i	2,156 **	** 2,156 6,200 JOtherdirectcosts
	grant accruals
				492,496		115,018	607,514	909,340
	Support costs (see note 8)			121,902		13,512	135,414	158,937
				614,398		128,530	742,928	1,068,277

The Urology Foundation annual report & financial statements 2021

THE UROLOGY FOUNDATION

NOTES TO THE FINANCIAL STATEMENTS for the year ended 31 December 2021

7. GRANT MAKING (Continued)

The Charity’s policy, in line with the Charities SORP 2019 is to recognise an expense and related liability for a research grant, at the point when the unconditional offer is conveyed to the recipient (see the accounting policy on page xx for further details). However, recipients do not always take up their research grants in full. Where this happens, in subsequent years, in order that the correct movement in the Charity’s liability is recognised, the expense as shown in the Statement of Financial Activities may not reflect the level of grant giving in the current year. A reconciliation to assist with users’ understanding of the grants awarded in the year, to the expense in the Statement of Financial Activities is provided below:

		Expense
Grants	Effects of	recognised in
awarded in the year ended 31 December	outstanding grant payments	the accounts for the year ended 31 December
2021		2021
5 (2020: 3) individuals
awarded to 4 (2020: 3) teams
luTiResearch aus RSMUrology Section		Ee
fravelGrantsPe Educationalcourse	PE P
879,422	(136,494)	742,928

The Urology Foundation annual report & financial statements 2021

THE UROLOGY FOUNDATION

NOTES TO THE FINANCIAL STATEMENTS

for the year ended 31 December 2021

----- Start of picture text -----
||||||||||||| |---|---|---|---|---|---|---|---|---|---|---|---| |Costs|of|Fundraising| |generating|trading:|Cost| |voluntary|of goods|Awareness|Giving| |income|sold|raising|grants|2021|2020| |7.5%|7.5%|30%|55%| |£|£|£|£|£|£| |SUPPORT AND AND|GOVERNANCE|COSTS|(UNRESTRICTED)| |Staff|costs|(see|note|9)|9,799|9,799|39,197|71,859|130,653|162,978| |Other|staff|costs|including|recruitment|1,868|1,868|7,473|13,700|24,909|2,565| |Committee|and|other|staff|welfare|expenses|25|25|100|183|333|574| |Other|office|costs|3,089|3,089|12,357|22,654|41,189|59,878| |Audit|fee|218|218|870|1,594|2,900|2,901| |Accountancy|and|advisory|services|980|980|3,920|7,186|13,066|15,192| |Other|costs|607|607|2,429|4,453|8,097|15,442| |Depreciation-owned|assets|37|37|149|273|496|546| |16,624|16,624|66,494|121,902|221,644|260,076|

----- End of picture text -----

8, SUPPORT AND AND GOVERNANCE COSTS (UNRESTRICTED)

8. SUPPORT AND GOVERNANCE COSTS (RESTRICTED)

----- Start of picture text -----
||||||||||||| |---|---|---|---|---|---|---|---|---|---|---|---| |Staff|costs|(see|note|9)|1,081|1,081|4,324|7,927|14,412|18,109| |Other|staff|costs|including|recruitment|211|211|844|1,547|2,813|285| |Committee|and|other|staff|welfare|expenses|3|3|11|20|37|64| |Other|office|costs|343|343|1,373|2,517|4,576|6,653| |Audit|fee|24|24|97|178|323|322| |Accountancy|and|advisory|services|109|109|436|799|1,453|1,688| |Other|costs|68|68|270|496|901|1,717| |Depreciation-owned|assets|4|4|17|30|55|64| |1,843|1,843|7,372|13,512|24,570|28,902|

----- End of picture text -----

The Urology Foundation annual report & financial statements 2021

THE UROLOGY FOUNDATION

NOTES TO THE FINANCIAL STATEMENTS

for the year ended 31 December 2021

----- Start of picture text -----
||||||||||| |---|---|---|---|---|---|---|---|---|---| |2021|2020| |STAFF|COSTS| |No.|No.| |The|average|monthly|number|of|persons|employed|by|the|charity| |(excluding|trustees)|during|the|period|was,|as|follows:| |Office|and|administration|ZF|3.5| |£|£| |Staff|costs|for|the|above|persons:| |Staff|Wages|and|salaries|51,800|84,690| |Staff|Social|security|costs|3,743|6,411| |Key|management|personnel|Wages|and|salaries|82,339|82,338| |Key|management|personnel|Social|security|costs|7,183|7,648| |145,065|181,087|

----- End of picture text -----

One employee received total emoluments in excess of £60,000 per annum during the period ended 31 December 2021. The total emoluments of this employee during the year were in the following ranges:

2021 2020

The Charity considers its key management personnel comprise the Chief Executive, with remuneration as noted above. In setting salary levels, The Urology Foundation follows the National Council for Voluntary Organisation’s advice that a charity’s pay policy should be to offer fair pay to attract and keep appropriately-qualified staff to lead, manage, support and/or deliver the charity’s aims. It also conducts online research of charity salaries and uses surveys to benchmark levels of pay. The Urology Foundation does not automatically award its staff with annual salary increases, either incremental or cost of living.

No Director received any remuneration from the Company during the year (2020: Enil).

No trustee received any remuneration for services provided to the charity during the current or previous period. Trustees expenses reimbursed in respect of Trustee's meetings and travel for the year ended 31st December 2021 amounted to £0 paid to no Trustees (2020 £0 paid to no Trustees).

----- Start of picture text -----
||||| |---|---|---|---| |TANGIBLE|ASSETS|Office| |Equipment| |£| |Cost:| |1|January|2021|20,335| |Additions|2,159| |31|December|2021|22,494| |Depreciation:| |1|January|2021|18,517| |Charge|for|year|350| |31|December|2021|18,867| |Net|book|value:| |31|December|2021|3,627| |31|December|2020|1,818|

----- End of picture text -----

The Urology Foundation annual report & financial statements 2021

THE UROLOGY FOUNDATION

NOTES TO THE FINANCIAL STATEMENTS

for the year ended 31 December 2021

		2021	2020
		£	£
11.	INVESTMENTS
	Investments listed on a recognised stock exchange
	at market value:
	1 January 2021	3,595,733	2,189,975
	Transfers from cash	-	1,045,830
	Additions at cost	536,261	1,161,969
	Disposal proceeds	(852,452)	(1,162,282)
	Realised (losses)/gains	124,555	(49,621)
	Unrealised gains	253,173	409,862
	31 December 2021	3,657,270	3,595,733
	At the balance sheet date, the market value of the portfolio comprised:
	UK investments	3,657,270	3,595,733
		3,657,270	3,595,733
	Fixed income securities	543,742	750,830
	Equities	-	-
	Multi-Asset & Hybrid Instruments	3,113,528	2,844,903
		3,657,270	3,595,733

At the balance sheet date, the historical cost of the investments was £2,938,371 (2020: £3,185,794). The following holdings had a value of >5% of the market value of the investments:

			Value	£	Value £
	Name	Holding	2021		2020
	Rothschild & CoWM SICAV-SIF Exbury Fund GBP	116,874	3,113,528		2,844,903
	Pentairs QIAIF PLC - Vanda Fund Shs -F- USD Shs	-		-	-
	InstitutionalCash SeriesPLC - BlackRock ICS Sterling Liquidity Fur	543,715	543,742		750,830
12.	DEBTORS		2021		2020
			£		£
	Amounts falling due within one year:
	Other debtors			3,017	2,761
	Prepayments			21,450	19,574
	Accrued Income			74,256	55,438
				98,723	77,773

The Urology Foundation annual report & financial statements 2021

THE UROLOGY FOUNDATION

NOTES TO THE FINANCIAL STATEMENTS for the year ended 31 December 2021

	13.	13.	CREDITORS											2021	2020
														£	£
			Amounts falling due within one			year:
			Deferred income											80,628	34,778
			General accruals											11,270	10,895
			Grant accruals											1,041,624	1,193,088
														1,133,522	1,238,761
			Deferred income b/fwd at 1 January						2021					34,778
			Amounts released	in	the year									(34,778)
			New amounts deferred in the year											80,628
			Deferred income c/fwd at 31 December 2021											80,628
			CREDITORS											2021	2020
														£	£
			Amounts falling due in more than				one year:
			Grant accruals											416,634	495,249
														416,634	495,249
	14.		RECONCILIATION	OF	NET INCOME/(EXPENDITURE) TO						NET CASHFLOW		FROM	OPERATING ACTIVITIES
			Net Income/(expenditure) for			the		reporting period
			perthe statement of financial			activities								289,461	560,431
			Adjustments for:
			Depreciation charges											350	606
			(Gains) on investments											(377,727)	(360,241)
			Dividends and interest from investments											(41,002)	(291)
			Management fees	paid from investments										72	365
			(Increase)/Decrease		in debtors									(20,950)	53,262
			(Decrease)/Increase		in creditors									(183,855)	719,139
			Net cash used in	operating activities										(333,651)	973,271
	15.		THE FUNDS OF THE CHARITY
				1 January										Gains/(losses)	31 December
				2021		Transfer				Income		Expenditure		on Investments	2021
					£			£		£		£		£	£
Restricted income
funds:
Robotic Surgery
Training Fund					196,287				-		(94)		3,641	242	200,076
Prostate Cancer			Research Fund		103,370				-		-	35,340		94	138,804
Bladder Cancer			Fund		149,860				-		-	(181,360)		75	(31,425)
Travel	Fellowship Fund				652				-		-		-	1	653
‘EQUIP’		Quality & Safety Pilot			30,889		(35,389)				6,194	(1,748)		54	-
Team Corbs - Testicular					1,823				.		332		-	3	2,158
Charles		Reynolds			-				-		40,500		-	3	40,503
					482,881		(35,389)				46,932	(144,128)		472	350,768
Unrestricted income funds:
General Fund				1,139,859				35,768		763,999		(719,765)		377,255	1,597,116
Designated Fund (R. Shackman)					35,683				(379)		-	(35,304)		-	-
Designated Fund (BUF)					500,000				-		-		-	-	500,000
				2,158,423					-	810,931		(899,197)		377,727	2,447,884

The Urology Foundation annual report & financial statements 2021

THE UROLOGY FOUNDATION

NOTES TO THE FINANCIAL STATEMENTS for the year ended 31 December 2021

THE FUNDS OF THE CHARITY (Continued)
e The trustees have designated the original 1995 start-up funding for the BUF of £500,000 as the trustees feel strongly that The Foundation should seek to maintain reserves sufficient to continue to fund its objectives on a long term basis.
e Ralph Shackman Trust - The Ralph Shackman Trust’s aims were similar to TUF, being to advance the study of urology through grants and awards and funding clinical visits. In 2012 the Trust asked TUF to assist them in promoting and administering their clinical visit grants. In 2015 the Trust wound down and transferred its remaining assets to TUF. This included the responsibilities for administering the Keith Yeates Medal, an Award given to the Urology Trainee who receives the highest marks in the Intercollegiate Specialist Exams in Urology. This award comes with a prize of £2,000 for a TUF/Shackman travelling fellowship.
° The Robotic Surgery Training Fund was set up in 2009 following the receipt of restricted donation income from the British Urological Foundation and a generous private donation. The funds are mainly used to award grants towards robotically assisted surgery training, education, and research into robotic training techniques.
e Bladder cancer remains one of the most expensive cancers to treat and survival rates appear to have reached a plateau at 50%. In the UK, more than 10,000 new cases of bladder cancer are diagnosed every year. The Foundation is determined to improve the diagnosis, treatment and outcomes of people with bladder cancer and to allocate resources to vital research into the diagnosis and pathology of bladder cancer and to funding training and education to improve patient treatment and care. Through a generous donation from The Champniss Foundation, TUF has funded the iROC bladder cancer surgery trial, investigating the efficacy of Robot assisted radical cystectomy and intracorporeal urinary diversion compared with open radical cystectomy in patients with bladder cancer. The Champniss Foundation and the Champniss Charitable Trust are also funding a study into patient tracking post-surgery via fitness devices.
e Prostate Cancer Research - Thanks to the John Black Charitable Foundation (JBCF) TUF has been able to invest in a number of high profile research studies, such as the CLIMATE trial, which are ongoing. There were no new JBCF awards given in 2021.
e Education in Quality Improvement Programme (EQUIP) - The Urology Foundation is keen to deliver real improvements in patient care, while also developing urologists and equipping them to become leaders of the future. We supported the development of the EQUIP training programme, that equips urologists with the skills required to analyse current practise and to develop collaborative quality improvement work, and to share learning and best practices with their peers and urology departments regionally and nationally. This programme has now been incorporated into the urology curriculum and the anticipated benefits will be improved patient safety and care that will reflect a culture that fosters continuous improvement. We are grateful to the Schroder Foundation and a number of other funders for their generous support of the programme.
° The Foundation started working with former England and Lions rugby champion, Alex Corbisiero, to raise funds for research into testicular cancer, following Alex’s diagnosis. A Just Giving page has been set up and the charity will continue to fundraise with Alex.

()

The Urology Foundation annual report & financial statements 2021

THE UROLOGY FOUNDATION

NOTES TO THE FINANCIAL STATEMENTS

for the year ended 31 December 2021

16. ANALYSIS OF NET ASSETS BETWEEN FUNDS

			Fixed	Net
			Assets	Assets/(Liabilities)	Total
			£	£	£
	Restricted income funds:
	Robotic Surgery Training Fund		200,076	-	200,076
	Prostate Cancer Research Fund		982,367	(843,563)	138,804
	Bladder Cancer Fund		149,934	(181,359)	(31,425)
	Travel Fellowship Fund		1,123	(470)	653
	Team Corbs - Testicular		-	2,158	2,158
	Charles Reynolds		-	40,503	40,503
	Unrestricted income funds:
	General Fund		1,827,397	(230,281)	1,597,116
	Designated Fund (Ralph Shackman)		-	-	-
	Designated Fund (British Urology Foundation)		500,000	:	500,000
	NET ASSETS		3,660,897	(1,213,013)	2,447,884
17.	ULTIMATE CONTROLLING PARTY
	The Charity is controlled by the board of Trustees.
18.	COMMITMENTS UNDER OPERATING LEASES
	As at 31st December 2021, the Charity had annualised operating		commitments	under non-cancellable
	operating leases expiring as follows:	2021		2020
		£		£
	Expiring within one year
	- Land and Buildings	28,700		49,200
	- Others	1,566		3,132
		30,266		52,332
	Expiring within two to five years
	- Land and Buildings	-		28,700
	- Others	-		1,566
		-		29,366

CONTINGENT ASSETS

As at 31st December 2019, the Trustees were aware of a Legacy which is due to The Urology Foundation. The Legacy is the balance of the sale of a property, a 14% share of the estate was bequeathed to the Charity in 2013/2014. £9,000 was received in 2020 and a further £4,580 was expected and paid in 2022 and has been accrued into the 31st December 2021 accounts.

20. RELATED PARTY TRANSACTIONS

There were no related party transactions in the period under review or in the prior year.

The Urology Foundation annual report & financial statements 2021

UROFOUNDATIONLoGy('\

THE UROLOGY FOUNDATION

Contents

Chairman’s statement

Overview of the year

Objectives and Activities

Our Vision and Mission

Our Aims

Our Values

What we do

Public Benefit

Grants policy

Comparison of 2020 v 2021 An Overview

Achievements and Performance in 2021

1. Seeking better treatments and cures through research

Five projects were selected for funding:

Support for urology trainees

Support for urology nurses

()

4. Plans for the future

Financial Review

Fundraising

Reserves & Liquidity Policy

Statement of going concern

Investments Policy

Remuneration policy

Pensions policy

Equal opportunities and diversity policy

Principal risks and uncertainties

Impact of Covid-19 and war in Ukraine

Risks to Data

Structure, Governance & Management

Charity Governance Code

Trustee Recruitment, Training and Induction

Appointment & Election

The Executive Team

Scientific and Education Committee (SEC)

Research Scholarship Review Panel

Finance Committee

Relationships with Related Parties

Representation on Other Bodies

Reference and administrative details

Trustees

Trustees’ & Directors’ Responsibilities in the Preparation of Financial Statements

Auditor

Statement as to disclosure of information to the auditor

Annex A

Report of the Independent Auditors to the Trustees of The Urology Foundation (Registered number: 06817868)

Opinion

In our opinion the financial statements:

Basis for opinion

Conclusions relating to going concern

Other information

Matters on which we are required to report by exception

financial statements; or

Report of the Independent Auditors to the Trustees of The Urology Foundation (Registered number: 06817868)

Responsibilities of trustees

Identifying and assessing potential risks related to irregularities

Audit response to risks identified

Report of the Independent Auditors to the Trustees of The Urology Foundation (Registered number: 06817868)

—_—

THE UROLOGY FOUNDATION

STATEMENT OF FINANCIAL ACTIVITIES

THE UROLOGY FOUNDATION

STATEMENT OF FINANCIAL ACTIVITIES

THE UROLOGY FOUNDATION

BALANCE SHEET

THE UROLOGY FOUNDATION

THE UROLOGY FOUNDATION

Financial statements for the year ended 31 December 2021

ACCOUNTING POLICIES

BASIS OF ACCOUNTING

INCOME

EXPENDITURE

TANGIBLE FIXED ASSETS

Office equipment

25% reducing balance

OPERATING LEASES

THE UROLOGY FOUNDATION